Short answer
FATE THERAPEUTICS INC (FATE) filed its Q1 2026 10-Q quarterly report on May 13, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $1M (down 20.3% year over year) with net income of −$31M.
Q1 2026 key financials · XBRL
- Revenue
- $1M
- −20.3% YoY
- Net income
- −$31M
- +17.0% YoY
- Operating margin
- -2540.4%
- EPS (diluted)
- −$0.26
- +18.8% YoY
Source: XBRL data from the FATE THERAPEUTICS INC (FATE) Q1 2026 10-Q on SEC EDGAR. USD.
FATE THERAPEUTICS INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $1.3M, down $0.3M YoY from $1.6M
- R&D expense $24.7M, down $4.4M YoY from $29.1M
- G&A expense $9.6M, down $4.2M YoY from $13.8M
- CIRM liabilities $10.6M received, including $6.6M for FT819 and $4.0M for FT836
- Funding sufficient for at least twelve months; ongoing losses and capital-raising needs remain headwinds
Risk Factors
- No new or changed risk factors identifiable; supplied excerpt contains standard carried-forward disclosures without quarter-specific updates
- Regulatory risk: no product candidate has FDA approval, leaving revenue dependent on future clinical and regulatory success
- Operational risk: iPSC-derived cell therapy manufacturing remains unvalidated for commercial production
- Competitive risk: approved agents or changed standards of care could require additional trials or make programs obsolete
- Supply-chain risk: shortages of cyclophosphamide, fludarabine, or monoclonal antibodies could delay clinical trials
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other FATE THERAPEUTICS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.